8-(2,4-dichlorophenyl)-4-(5-carbamoyl-1,2,3,6-tetrahydropyridin-1-yl)-2-methylquinoline | 388122-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-(2,4-dichlorophenyl)-4-(5-carbamoyl-1,2,3,6-tetrahydropyridin-1-yl)-2-methylquinoline
• 英文别名: 1-[8-(2,4-dichlorophenyl)-2-methylquinolin-4-yl]-3,6-dihydro-2H-pyridine-5-carboxamide
• CAS: 388122-62-1
• 化学式: C₂₂H₁₉Cl₂N₃O
• 分子量: 412.318
• InChiKey: KJQVZKYNXDWTPL-UHFFFAOYSA-N

物化性质

• 沸点：
  633.8±55.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Tetrahydropyridino or piperidino heterocylic derivatives
  申请人：——

  公开号：US20040034061A1

  公开（公告）日：2004-02-19

  A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula [I]: A-Het  [I] has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  一种由公式[I]表示的四氢吡啶或哌啶杂环衍生物：A-Het，[I]具有高亲和力对抗CRF受体，并对CRF被认为参与的疾病有效。
• Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
  申请人：Aventis Pharma S.A.

  公开号：US20040209861A1

  公开（公告）日：2004-10-21

  The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.

  本发明涉及一种或多种CB1拮抗剂氮杂环衍生物和一种或多种促进脑内多巴胺能神经传递的产物的组合，以及包含它们的制药组合物，用于治疗帕金森病。
• [EN] TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES DE TÉTRAHDYROPYRIDINO OU DE PIPÉRIDINO
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2002002549A1

  公开（公告）日：2002-01-10

  A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula [I]: A-Het [I]has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  一种由公式[I]表示的四氢吡啶或哌啶杂环衍生物，其中A-Het [I]具有高亲和力的CRF受体，并且对于CRF被认为参与的疾病是有效的。
• Tetrahydropyridin or piperidino heterocyclic derivatives
  申请人：Nakazato Atsuro

  公开号：US20050009874A1

  公开（公告）日：2005-01-13

  A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula [I]: A-Het   [I] has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  一种由公式[I]表示的四氢吡啶或哌啶杂环衍生物，其中A-Het，具有高亲和力CRF受体，并且对于CRF被认为参与的疾病是有效的。
• TETRAHYDROPYRIDINO OR PIPERIDINO HETEROCYCLIC DERIVATIVES
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1299378A1

  公开（公告）日：2003-04-09